Eisai Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eisai Co., Ltd.
The COVID-19 pandemic is serving as a catalyst to draw attention to other destructive infectious diseases that continue to ravage communities across the world. This is to be welcomed, but we must also ask what we have learnt from our recent experiences that can be deployed to help accelerate approaches to fighting other, similarly devastating, established and emerging infectious diseases.
BinaxNOW rapid tests, the size of a credit card with no other equipment required, are sold directly to organizations at $5 each and an at-home version, with use guided through digital links, is available at $25 per test. It can be paired with NAVICA app, allowing consumers to display negative results through a temporary digital health certificate.
Office of Prescription Drug Promotion issued just six letters citing companies for improper drug promotion in 2020, including the placement of safety information in an email and making unfounded COVID-19 claims. New research projects focus on celebrity endorsements, medical conference materials.
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
- Other Names / Subsidiaries
- EA Pharma Co., Ltd.
- Eisai China Inc
- Eisai Laboratorios
- Eisai Mexico
- Eisai Participacoes Ltda. (Brazil Subsidiary)
- H3 Biomedicine
- HI-Eisai Pharmaceutical Inc.
- Jingyi Weixiang (Shanghai) Health Industry Development Limited
- Liaoning TianYi Biological Pharmaceutical Co., Ltd.
- KAN Research Institute, Inc.
- MGI Pharma, Inc.
- Morphotek, Inc.
- Zycos Inc.
- Eisai Vietnam Co., Ltd.